Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

The Eosinophilic Esophagitis Histology Scoring System (EoEHSS) scores, evaluating the EoE severity and extent, exhibited a mean 39% decline in Composite Stage and a 37% decline in Composite Grade ...

Diseases & Conditions Pathology of Eosinophilic Esophagitis (EoE) 2001 /viewarticle/1001600 ...

Diseases & Conditions Pathology of Eosinophilic Esophagitis (EoE) 2002 1610393-overview ...

The study enrolled 430 patients with active eosinophilic esophagitis and no response to at least 8 weeks of treatment with PPIs. Across the groups, mean age was 35-36 (6-12% were adolescents), 63 ...

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis ...

Eupraxia Pharmaceuticals has disclosed additional positive data from its Phase Ib/IIa RESOLVE clinical trial of EP-104GI in treating eosinophilic esophagitis (EoE). The multicentre, open-label ...

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis ...

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis ...